▲ +411.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $42.00, with a high forecast of $42.00 and a low forecast of $42.00. The average price target represents a 411.57% upside from the last price of $8.21.
The current consensus among 1 polled investment analysts is to buy stock in Opiant Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.